Neurogene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Neurogene Inc. (NGNE) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $31.10 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-11
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $31.10M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $7.20M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $6.10M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $2.90M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $31.10M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $7.20M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $6.10M 10-K · filed 2026-03-24 |
| 2025-09-30 | $2.90M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.50M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $700.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $4.30M 10-K · filed 2025-03-24 |
| 2024-09-30 | $20.00M 10-Q · filed 2024-11-18 |
| 2024-06-30 | $13.50M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $32.20M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $2.60M 10-K · filed 2024-03-18 |
| 2023-09-30 | $4.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $11.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $3.00K 10-Q · filed 2023-05-08 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-14 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 |
| 2022-06-30 | $4.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $28.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $6.91M 10-K · filed 2023-03-20 |
| 2021-09-30 | $18.38M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $26.29M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $40.71M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $53.13M 10-K · filed 2022-03-01 |
| 2020-09-30 | $42.14M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $66.95M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $40.43M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $45.04M 10-K · filed 2021-03-25 |
| 2019-09-30 | $3.00K 10-Q · filed 2019-11-13 |
| 2018-03-31 | $5.88M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $3.19M 10-K · filed 2019-03-07 |
| 2017-09-30 | $6.28M 10-Q · filed 2017-11-08 |
| 2016-12-31 | $9.83M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |